The changing landscape of optic neuritis: a narrative review.
Demyelinating diseases
Multiple sclerosis
Optic nerve diseases
Optic neuritis
Journal
Journal of neurology
ISSN: 1432-1459
Titre abrégé: J Neurol
Pays: Germany
ID NLM: 0423161
Informations de publication
Date de publication:
Jan 2022
Jan 2022
Historique:
received:
10
09
2020
accepted:
04
12
2020
revised:
02
12
2020
pubmed:
4
1
2021
medline:
11
1
2022
entrez:
3
1
2021
Statut:
ppublish
Résumé
Optic neuritis (ON) is an inflammatory optic neuropathy that is often a harbinger of central nervous system (CNS) demyelinating disorders. ON is frequently misdiagnosed in the clinical arena, leading to either inappropriate management or diagnostic delays. As a result, patients may fail to achieve optimal recovery. The treatment response to corticosteroids and long term risk of multiple sclerosis was established in the first clinical trials conducted roughly 30 years ago. Spontaneous resolution was observed in the vast majority of patients and intravenous high-dose corticosteroids hastened recovery; half of the patients eventually developed multiple sclerosis. Over the ensuing decades, the number of inflammatory conditions associated with ON has significantly expanded exposing substantial variability in the prognosis, treatment, and management of ON patients. ON subtypes can frequently be distinguished by distinct clinical, serological, and radiological profiles allowing expedited and specialized treatment. Guided by an increased understanding of the immunopathology underlying optic nerve and associated CNS injuries, novel disease management strategies are emerging to minimize vision loss, improve long-term surveillance strategies, and minimize CNS injury and disability. Knowledge regarding the clinical signs and symptoms of different ON subtypes is essential to guide acute therapy, prognosticate recovery, accurately identify underlying CNS inflammatory disorders, and facilitate study design for the next generation of clinical and translational trials.
Identifiants
pubmed: 33389032
doi: 10.1007/s00415-020-10352-1
pii: 10.1007/s00415-020-10352-1
pmc: PMC8253868
mid: NIHMS1659506
doi:
Substances chimiques
Adrenal Cortex Hormones
0
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
111-124Subventions
Organisme : NEI NIH HHS
ID : K23 EY027849
Pays : United States
Organisme : NEI NIH HHS
ID : R01 EY022936
Pays : United States
Organisme : NINDS NIH HHS
ID : R01 NS115488
Pays : United States
Organisme : NEI NIH HHS
ID : K23EY027849
Pays : United States
Organisme : NEI NIH HHS
ID : K23EY027849
Pays : United States
Informations de copyright
© 2021. Springer-Verlag GmbH Germany, part of Springer Nature.
Références
Rodriguez M et al (1995) Optic neuritis: a population-based study in Olmsted County Minnesota. Neurology 45(2):244–250
pubmed: 7854520
doi: 10.1212/WNL.45.2.244
Percy AK, Nobrega FT, Kurland LT (1972) Optic neuritis and multiple sclerosis An epidemiologic study. Arch Ophthalmol 87(2):135–139
pubmed: 5057861
doi: 10.1001/archopht.1972.01000020137004
Martínez-Lapiscina EH et al (2014) Is the incidence of optic neuritis rising? Evidence from an epidemiological study in Barcelona (Spain), 2008–2012. J Neurol 261(4):759–767
pubmed: 24532201
doi: 10.1007/s00415-014-7266-2
Soelberg K et al (2017) A population-based prospective study of optic neuritis. Multiple sclerosis (Houndmills, Basingstoke, England) 23(14):1893–1901
doi: 10.1177/1352458517734070
Woung LC et al (2007) Optic neuritis among National Health Insurance enrollees in Taiwan, 2000–2004. Neuroepidemiology 29(3–4):250–254
pubmed: 18176082
doi: 10.1159/000112858
Stunkel L et al (2018) Incidence and causes of overdiagnosis of optic neuritis. JAMA Ophthalmol 136(1):76–81
pubmed: 29222573
doi: 10.1001/jamaophthalmol.2017.5470
Beck RW et al (1992) A randomized, controlled trial of corticosteroids in the treatment of acute optic neuritis. The Optic Neuritis Study Group. N Engl J Med 326(9):581–588
pubmed: 1734247
doi: 10.1056/NEJM199202273260901
Chen JJ et al (2018) Optic disc edema in glial fibrillary acidic protein autoantibody-positive meningoencephalitis. J Neuroophthalmol 38(3):276–281
pubmed: 29210929
doi: 10.1097/WNO.0000000000000593
Mealy MA et al (2012) Epidemiology of neuromyelitis optica in the United States: a multicenter analysis. Arch Neurol 69(9):1176–1180
pubmed: 22733096
doi: 10.1001/archneurol.2012.314
Papais-Alvarenga RM et al (2008) Clinical course of optic neuritis in patients with relapsing neuromyelitis optica. Arch Ophthalmol 126(1):12–16
pubmed: 18195212
doi: 10.1001/archophthalmol.2007.26
Chen JJ et al (2018) Myelin Oligodendrocyte glycoprotein antibody-positive optic neuritis: clinical characteristics, radiologic clues, and outcome. Am J Ophthalmol 195:8–15
pubmed: 30055153
pmcid: 6371779
doi: 10.1016/j.ajo.2018.07.020
The clinical profile of optic neuritis (1991) Experience of the optic neuritis treatment trial optic neuritis study group. Arch Ophthalmol 109(12):1673–1678
doi: 10.1001/archopht.1991.01080120057025
Bennett JL (2019) Optic Neuritis. Continuum (Minneap Minn) 25(5):1236–1264
Merle H et al (2012) Treatment of optic neuritis by plasma exchange (add-on) in neuromyelitis optica. Arch Ophthalmol 130(7):858–862
pubmed: 22776923
doi: 10.1001/archophthalmol.2012.1126
Sato DK et al (2014) Distinction between MOG antibody-positive and AQP4 antibody-positive NMO spectrum disorders. Neurology 82(6):474–481
pubmed: 24415568
pmcid: 3937859
doi: 10.1212/WNL.0000000000000101
Costello F (2014) Inflammatory optic neuropathies. Continuum (Minneap Minn), 2014. 20(4 Neuro-ophthalmology): pp 816–37.
Taylor TR et al (2020) Prevalence and demographics of multiple sclerosis-associated uveitis: a UK biobank study. Mult Scler Relat Disord 43:102209
pubmed: 32480346
doi: 10.1016/j.msard.2020.102209
Ramanathan S et al (2019) Uveitis and optic perineuritis in the context of myelin oligodendrocyte glycoprotein antibody seropositivity. Eur J Neurol 26(8):1137-e75
pubmed: 30748058
doi: 10.1111/ene.13932
Chen JJACF (2018) The role of optical coherence tomography in neuro-ophthalmology. Ann Eye Sci 3(6).
Horton L, Bennett JL (2018) Acute management of optic neuritis: an evolving paradigm. J Neuroophthalmol 38(3):358–367
pubmed: 30106803
pmcid: 6370553
doi: 10.1097/WNO.0000000000000700
Hokari M et al (2016) Clinicopathological features in anterior visual pathway in neuromyelitis optica. Ann Neurol 79(4):605–24
pubmed: 26836302
doi: 10.1002/ana.24608
Tsoi VL et al (2006) Immunohistochemical evidence of inducible nitric oxide synthase and nitrotyrosine in a case of clinically isolated optic neuritis. J Neuroophthalmol 26(2):87–94
pubmed: 16845306
doi: 10.1097/01.wno.0000223266.48447.1b
Lennon VA et al (2004) A serum autoantibody marker of neuromyelitis optica: distinction from multiple sclerosis. Lancet 364(9451):2106–12
pubmed: 15589308
doi: 10.1016/S0140-6736(04)17551-X
Lennon VA et al (2005) IgG marker of optic-spinal multiple sclerosis binds to the aquaporin-4 water channel. J Exp Med 202(4):473–7
pubmed: 16087714
pmcid: 2212860
doi: 10.1084/jem.20050304
Asavapanumas N et al (2014) Experimental mouse model of optic neuritis with inflammatory demyelination produced by passive transfer of neuromyelitis optica-immunoglobulin G. J Neuroinflammation 11:16
pubmed: 24468108
pmcid: 3909205
doi: 10.1186/1742-2094-11-16
Bennett JL et al (2009) Intrathecal pathogenic anti-aquaporin-4 antibodies in early neuromyelitis optica. Ann Neurol 66(5):617–29
pubmed: 19938104
pmcid: 3180961
doi: 10.1002/ana.21802
Duan T, Smith AJ, Verkman AS (2018) Complement-dependent bystander injury to neurons in AQP4-IgG seropositive neuromyelitis optica. J Neuroinflammation 15(1):294
pubmed: 30348195
pmcid: 6198534
doi: 10.1186/s12974-018-1333-z
Hillebrand S et al (2019) Circulating AQP4-specific auto-antibodies alone can induce neuromyelitis optica spectrum disorder in the rat. Acta Neuropathol 137(3):467–485
pubmed: 30564980
doi: 10.1007/s00401-018-1950-8
Weil MT et al (2016) Loss of myelin basic protein function triggers myelin breakdown in models of demyelinating diseases. Cell Rep 16(2):314–322
pubmed: 27346352
pmcid: 4949381
doi: 10.1016/j.celrep.2016.06.008
Herwerth M et al (2016) In vivo imaging reveals rapid astrocyte depletion and axon damage in a model of neuromyelitis optica-related pathology. Ann Neurol 79(5):794–805
pubmed: 26946517
pmcid: 5021140
doi: 10.1002/ana.24630
Zhang H, Bennett JL, Verkman AS (2011) Ex vivo spinal cord slice model of neuromyelitis optica reveals novel immunopathogenic mechanisms. Ann Neurol 70(6):943–54
pubmed: 22069219
pmcid: 3319401
doi: 10.1002/ana.22551
Saadoun S et al (2010) Intra-cerebral injection of neuromyelitis optica immunoglobulin G and human complement produces neuromyelitis optica lesions in mice. Brain 133(Pt 2):349–61
pubmed: 20047900
pmcid: 2822632
doi: 10.1093/brain/awp309
Peschl P et al (2017) Human antibodies against the myelin oligodendrocyte glycoprotein can cause complement-dependent demyelination. J Neuroinflammation 14(1):208
pubmed: 29070051
pmcid: 5657084
doi: 10.1186/s12974-017-0984-5
Spadaro M et al (2018) Pathogenicity of human antibodies against myelin oligodendrocyte glycoprotein. Ann Neurol 84(2):315–328
pubmed: 30014603
doi: 10.1002/ana.25291
Kitley J et al (2012) Myelin-oligodendrocyte glycoprotein antibodies in adults with a neuromyelitis optica phenotype. Neurology 79(12):1273–7
pubmed: 22914827
doi: 10.1212/WNL.0b013e31826aac4e
Probstel AK et al (2015) Anti-MOG antibodies are present in a subgroup of patients with a neuromyelitis optica phenotype. J Neuroinflammation 12:46
pubmed: 25889963
pmcid: 4359547
doi: 10.1186/s12974-015-0256-1
Manogaran P et al (2019) Retinal pathology in experimental optic neuritis is characterized by retrograde degeneration and gliosis. Acta Neuropathol Commun 7(1):116
pubmed: 31315675
pmcid: 6637505
doi: 10.1186/s40478-019-0768-5
Fang B et al (2016) Autoimmune glial fibrillary acidic protein astrocytopathy: a novel meningoencephalomyelitis. JAMA Neurol 73(11):1297–1307
pubmed: 27618707
doi: 10.1001/jamaneurol.2016.2549
Liu Y et al (2017) Myelin-specific multiple sclerosis antibodies cause complement-dependent oligodendrocyte loss and demyelination. Acta Neuropathol Commun 5(1):25
pubmed: 28340598
pmcid: 5366134
doi: 10.1186/s40478-017-0428-6
Bursztyn L, DLLB, Cornblath WT Sensitivity of Magnetic Resonance Imaging for Acute Demyelinating Optic Neuritis. 2015, North American Neuro-Ophthalmology Society Meeting, San Diego, CA
Kupersmith MJ et al (2002) Contrast-enhanced MRI in acute optic neuritis: relationship to visual performance. Brain 125(Pt 4):812–22
pubmed: 11912114
doi: 10.1093/brain/awf087
McKinney AM et al (2013) Accuracy of routine fat-suppressed FLAIR and diffusion-weighted images in detecting clinically evident acute optic neuritis. Acta Radiol 54(4):455–61
pubmed: 23386735
doi: 10.1177/0284185112471797
Storoni M et al (2013) Distinguishing optic neuritis in neuromyelitis optica spectrum disease from multiple sclerosis: a novel magnetic resonance imaging scoring system. J Neuroophthalmol 33(2):123–7
pubmed: 23609766
doi: 10.1097/WNO.0b013e318283c3ed
Traboulsee A et al (2016) Revised recommendations of the consortium of ms centers task force for a standardized MRI protocol and clinical guidelines for the diagnosis and follow-up of multiple sclerosis. AJNR Am J Neuroradiol 37(3):394–401
pubmed: 26564433
pmcid: 5094650
doi: 10.3174/ajnr.A4539
Majed M et al (2016) Clinical utility of testing AQP4-IgG in CSF: Guidance for physicians. Neurol Neuroimmunol Neuroinflamm 3(3):e231
pubmed: 27144221
pmcid: 4841640
doi: 10.1212/NXI.0000000000000231
Gal RL, Vedula SS, Beck R Corticosteroids for treating optic neuritis. Cochrane Database Syst Rev, 2015(8): CD001430.
De Lott LB et al (2020) Association of individual-level factors with visual outcomes in optic neuritis: secondary analysis of a randomized clinical trial. JAMA Netw Open 3(5):e204339
pubmed: 32379333
pmcid: 7206503
doi: 10.1001/jamanetworkopen.2020.4339
Morrow SA et al (2018) Effect of treating acute optic neuritis with bioequivalent oral vs intravenous corticosteroids: a randomized clinical trial. JAMA Neurol 75(6):690–696
pubmed: 29507942
pmcid: 5885218
doi: 10.1001/jamaneurol.2018.0024
Chen JJ et al (2018) Prevalence of myelin oligodendrocyte glycoprotein and aquaporin-4-IgG in patients in the optic neuritis treatment trial. JAMA Ophthalmol 136(4):419–422
pubmed: 29470571
pmcid: 5876803
doi: 10.1001/jamaophthalmol.2017.6757
Kleiter I et al (2016) Neuromyelitis optica: evaluation of 871 attacks and 1153 treatment courses. Ann Neurol 79(2):206–16
pubmed: 26537743
doi: 10.1002/ana.24554
Kleiter I et al (2018) Apheresis therapies for NMOSD attacks: a retrospective study of 207 therapeutic interventions. Neurol Neuroimmunol Neuroinflamm 5(6):e504
pubmed: 30345331
pmcid: 6192689
doi: 10.1212/NXI.0000000000000504
Bonnan M et al (2018) Short delay to initiate plasma exchange is the strongest predictor of outcome in severe attacks of NMO spectrum disorders. J Neurol Neurosurg Psychiatry 89(4):346–351
pubmed: 29030418
doi: 10.1136/jnnp-2017-316286
Thompson AJ et al (2018) Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria. Lancet Neurol 17(2):162–173
pubmed: 29275977
doi: 10.1016/S1474-4422(17)30470-2
Rae-Grant A et al (2018) Practice guideline recommendations summary: disease-modifying therapies for adults with multiple sclerosis: report of the guideline development, dissemination, and implementation subcommittee of the American academy of neurology. Neurology 90(17):777–788
pubmed: 29686116
doi: 10.1212/WNL.0000000000005347
Excellence NIfHaC Multiple sclerosis in adults: management. 2014 November, 11, 2019 [cited 2020 November 27]. https://www.nice.org.uk/guidance/cg186/chapter/Recommendations#diagnosing-ms .
Wingerchuk DM et al (2015) International consensus diagnostic criteria for neuromyelitis optica spectrum disorders. Neurology 85(2):177–89
pubmed: 26092914
pmcid: 4515040
doi: 10.1212/WNL.0000000000001729
Romeo AR, Segal BM (2019) Treatment of neuromyelitis optica spectrum disorders. Curr Opin Rheumatol 31(3):250–255
pubmed: 30920972
doi: 10.1097/BOR.0000000000000603
Damato V, Evoli A, Iorio R (2016) Efficacy and safety of rituximab therapy in neuromyelitis optica spectrum disorders: a systematic review and meta-analysis. JAMA Neurol 73(11):1342–1348
pubmed: 27668357
doi: 10.1001/jamaneurol.2016.1637
Bichuetti DB et al (2019) Treating neuromyelitis optica with azathioprine: 20-year clinical practice. Mult Scler 25(8):1150–1161
pubmed: 29761736
doi: 10.1177/1352458518776584
Costanzi C et al (2011) Azathioprine: tolerability, efficacy, and predictors of benefit in neuromyelitis optica. Neurology 77(7):659–66
pubmed: 21813788
doi: 10.1212/WNL.0b013e31822a2780
Huang Q et al (2018) Low-dose mycophenolate mofetil for treatment of neuromyelitis optica spectrum disorders: a prospective multicenter study in South China. Front Immunol 9:2066
pubmed: 30258442
pmcid: 6143768
doi: 10.3389/fimmu.2018.02066
Watanabe S et al (2007) Low-dose corticosteroids reduce relapses in neuromyelitis optica: a retrospective analysis. Mult Scler 13(8):968–74
pubmed: 17623727
doi: 10.1177/1352458507077189
Berger JR (2017) Classifying PML risk with disease modifying therapies. Mult Scler Relat Disord 12:59–63
pubmed: 28283109
doi: 10.1016/j.msard.2017.01.006
Pittock SJ et al (2019) Eculizumab in aquaporin-4-positive neuromyelitis optica spectrum disorder. N Engl J Med 381(7):614–625
pubmed: 31050279
doi: 10.1056/NEJMoa1900866
Yamamura T et al (2019) Trial of satralizumab in neuromyelitis optica spectrum disorder. N Engl J Med 381(22):2114–2124
pubmed: 31774956
doi: 10.1056/NEJMoa1901747
Cree BA et al (2016) Placebo-controlled study in neuromyelitis optica-Ethical and design considerations. Mult Scler 22(7):862–72
pubmed: 26666258
doi: 10.1177/1352458515620934
de Mol CL et al (2020) The clinical spectrum and incidence of anti-MOG-associated acquired demyelinating syndromes in children and adults. Mult Scler 26(7):806–814
pubmed: 31094288
doi: 10.1177/1352458519845112
Jarius S et al. (2016) MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 2: Epidemiology, clinical presentation, radiological and laboratory features, treatment responses, and long-term outcome. J Neuroinflammation 13(1): 280.
Jarius S et al. (2016) MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 1: Frequency, syndrome specificity, influence of disease activity, long-term course, association with AQP4-IgG, and origin. J Neuroinflammation. 13(1): 279.
Jurynczyk M et al (2017) Clinical presentation and prognosis in MOG-antibody disease: a UK study. Brain 140(12):3128–3138
pubmed: 29136091
doi: 10.1093/brain/awx276
Lopez-Chiriboga S et al. Long-term outcomes in patients with myelin oligodendrocyte glycoprotein immunoglobulin g-associated disorder. JAMA Neurol 2020.
Chen JJ, Bhatti MT (2020) Clinical phenotype, radiological features, and treatment of myelin oligodendrocyte glycoprotein-immunoglobulin G (MOG-IgG) optic neuritis. Curr Opin Neurol 33(1):47–54
pubmed: 31743235
doi: 10.1097/WCO.0000000000000766
Chen JJ et al (2020) Steroid-sparing maintenance immunotherapy for MOG-IgG associated disorder. Neurology 95(2):e111–e120
pubmed: 32554760
pmcid: 7455322
doi: 10.1212/WNL.0000000000009758
Flanagan EP et al (2017) Glial fibrillary acidic protein immunoglobulin G as biomarker of autoimmune astrocytopathy: analysis of 102 patients. Ann Neurol 81(2):298–309
pubmed: 28120349
doi: 10.1002/ana.24881
Beck RW, Cleary PA, Backlund JC (1994) The course of visual recovery after optic neuritis. Experience of the optic neuritis treatment trial. Ophthalmology 101(11):1771–8
pubmed: 7800355
doi: 10.1016/S0161-6420(94)31103-1
Sabadia SB et al (2016) 20/40 or better visual acuity after optic neuritis: Not as good as we once thought? J Neuroophthalmol 36(4):369–376
pubmed: 27472185
doi: 10.1097/WNO.0000000000000421
Moss HE et al (2014) Association of race/ethnicity with visual outcomes following acute optic neuritis: an analysis of the optic neuritis treatment trial. JAMA Ophthalmol 132(4):421–7
pubmed: 24557028
pmcid: 4115276
doi: 10.1001/jamaophthalmol.2013.7995
Costello F et al (2012) Sex-specific differences in retinal nerve fiber layer thinning after acute optic neuritis. Neurology 79(18):1866–72
pubmed: 23077012
pmcid: 3525310
doi: 10.1212/WNL.0b013e318271f755
Wingerchuk DM et al (1999) The clinical course of neuromyelitis optica (Devic’s syndrome). Neurology 53(5):1107–14
pubmed: 10496275
doi: 10.1212/WNL.53.5.1107
Merle H et al (2007) Natural history of the visual impairment of relapsing neuromyelitis optica. Ophthalmology 114(4):810–5
pubmed: 17141316
doi: 10.1016/j.ophtha.2006.06.060
White D et al (2019) Enlarged and enhancing optic nerves in advanced glial fibrillary acidic protein meningoencephalomyelitis. J Neuroophthalmol 39(3):411–415
pubmed: 31397693
doi: 10.1097/WNO.0000000000000842
Ruiz-Gaviria R et al (2015) Specificity and sensitivity of aquaporin 4 antibody detection tests in patients with neuromyelitis optica: a meta-analysis. Mult Scler Relat Disord 4(4):345–9
pubmed: 26195055
doi: 10.1016/j.msard.2015.06.003
Roed HG et al (2005) A double-blind, randomized trial of IV immunoglobulin treatment in acute optic neuritis. Neurology 64(5):804–10
pubmed: 15753413
doi: 10.1212/01.WNL.0000152873.82631.B3
Tsakiri A et al (2012) Simvastatin improves final visual outcome in acute optic neuritis: a randomized study. Mult Scler 18(1):72–81
pubmed: 21921071
doi: 10.1177/1352458511415452
Suhs KW et al (2012) A randomized, double-blind, phase 2 study of erythropoietin in optic neuritis. Ann Neurol 72(2):199–210
pubmed: 22926853
doi: 10.1002/ana.23573
Raftopoulos R et al (2016) Phenytoin for neuroprotection in patients with acute optic neuritis: a randomised, placebo-controlled, phase 2 trial. Lancet Neurol 15(3):259–69
pubmed: 26822749
doi: 10.1016/S1474-4422(16)00004-1
Cadavid D et al (2017) Safety and efficacy of opicinumab in acute optic neuritis (RENEW): a randomised, placebo-controlled, phase 2 trial. Lancet Neurol 16(3):189–199
pubmed: 28229892
doi: 10.1016/S1474-4422(16)30377-5
McKee JB et al (2019) Amiloride does not protect retinal nerve fibre layer thickness in optic neuritis in a phase 2 randomised controlled trial. Mult Scler 25(2):246–255
pubmed: 29172994
doi: 10.1177/1352458517742979
Albert C et al (2020) Fingolimod after a first unilateral episode of acute optic neuritis (MOVING)—preliminary results from a randomized, rater-blind, active-controlled, phase 2 trial. BMC Neurol 20(1):75
pubmed: 32126977
pmcid: 7052969
doi: 10.1186/s12883-020-01645-z
Falardeau J et al (2019) Oral lipoic acid as a treatment for acute optic neuritis: a blinded, placebo controlled randomized trial. Mult Scler J Exp Transl Clin 5(2):2055217319850193
pubmed: 31205740
pmcid: 6537072